{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:14:55Z","timestamp":1765545295056},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1972,3,1]],"date-time":"1972-03-01T00:00:00Z","timestamp":68256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1972,3,1]],"date-time":"1972-03-01T00:00:00Z","timestamp":68256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1972,3,1]],"date-time":"1972-03-01T00:00:00Z","timestamp":68256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[1972,3,1]],"date-time":"1972-03-01T00:00:00Z","timestamp":68256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[1972,3]]},"DOI":"10.1007\/bf00562501","type":"journal-article","created":{"date-parts":[[2004,11,20]],"date-time":"2004-11-20T12:42:49Z","timestamp":1100954569000},"page":"77-81","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["New indications for 6-azauridine treatment in man. A review"],"prefix":"10.1007","volume":"4","author":[{"given":"J.","family":"Elis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Ra\u0161kov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF00562501_CR1","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S0140-6736(60)90990-9","volume":"I","author":"D.J. Bauer","year":"1960","unstructured":"Bauer, D.J., Sadler, P.W.: New antiviral chemotherapeutic agent active against small-pox infection. Lancet1960 I, 1110\u20131111.","journal-title":"Lancet"},{"key":"BF00562501_CR2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0140-6736(63)90230-7","volume":"II","author":"D.J. Bauer","year":"1963","unstructured":"\u2014\u2014 Vincent, L.S., Kempe, C.H., Downie, A.W.: Prophylactic treatment of small-pox contacts with N-methylisatin-\u03b2-thiosemicarbazone (compound 33 I 57, Marboran). Lancet1963 II, 494\u2013496.","journal-title":"Lancet"},{"key":"BF00562501_CR3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1135\/cccc19640625","volume":"29","author":"J. Ber\u00e1nek","year":"1964","unstructured":"Ber\u00e1nek, J., Pitha, J.: Nucleic acid components and their analogues XLVI. Some derivates of 6-azacytidine and 6-azauridine. Coll. Czech. Chem. Comm.29, 625\u2013633 (1964).","journal-title":"Coll. Czech. Chem. Comm."},{"key":"BF00562501_CR4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1135\/cccc19630469","volume":"28","author":"J. Ber\u00e1nek","year":"1963","unstructured":"\u2014\u2014 \u0160orm, F.: Nucleic acid components and their analogues XXIX. The synthesis of 6-azacytidine-5\u2032-phosphate and 5\u2032-diphosphate. Coll. Czech. Chem. Comm.28, 469\u2013480 (1963).","journal-title":"Coll. Czech. Chem. Comm."},{"key":"BF00562501_CR5","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.7326\/0003-4819-65-5-1050","volume":"65","author":"C.J. Breeden","year":"1966","unstructured":"Breeden, C.J., Hall, T.C., Tyler, H.R.: Herpes simplex encephalitis treated with systemic 5-iodo-2\u2032-deoxyuridine. Ann. intern. Med.65, 1050\u20131056 (1966).","journal-title":"Ann. intern. Med."},{"key":"BF00562501_CR6","first-page":"366","volume":"45","author":"P.R.J. Burch","year":"1966","unstructured":"Burch, P.R.J., Rowell, N.R.: Psoriasis: Aetiological aspects. Acta derm.-venerol. (Stockh.)45, 366\u2013373 (1966).","journal-title":"Acta derm.-venerol."},{"key":"BF00562501_CR7","first-page":"1260","volume":"23","author":"P. Calabresi","year":"1963","unstructured":"Calabresi, P.: Current status of clinical investigations with 6-azauridine, 5-iodo-2\u2032-deoxyuridine and related derivates. Cancer Res.23, 1260\u20131261 (1963).","journal-title":"Cancer Res."},{"key":"BF00562501_CR8","first-page":"10","volume":"5","author":"P. Calabresi","year":"1964","unstructured":"Calabresi, P., Turner, R., Lefkowitz E.R.: Beneficial effects of azauridine in psoriasis and mycosis fungoides. Proc. Amer. Ass. Cancer Res.5, 10 (1964).","journal-title":"Proc. Amer. Ass. Cancer Res."},{"key":"BF00562501_CR9","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/0003-4819-64-2-352","volume":"64","author":"P. Calabresi","year":"1966","unstructured":"\u2014\u2014 \u2014\u2014 Beneficial effects of triacetyl-azauridine in psoriasis and mycosis fungoides. Ann. intern. Med.64, 352\u2013371 (1966).","journal-title":"Ann. intern. Med."},{"key":"BF00562501_CR10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2133.1964.tb15501.x","volume":"76","author":"D.K.W. Cotton","year":"1964","unstructured":"Cotton, D.K.W., Mier, P.D.: An hypothesis on the selectivity of psoriasis. Brit. J. Derm.76, 519\u2013520 (1964).","journal-title":"Brit. J. Derm."},{"key":"BF00562501_CR11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF00260120","volume":"245","author":"J. Elis","year":"1963","unstructured":"Elis, J., Jank\u016f, I.: Zur Pharmakologie des Azauracilribosids. Naunyn-Schmiedebergs Arch. Pharmak.245, 128\u2013129 (1963).","journal-title":"Naunyn-Schmiedebergs Arch. Pharmak."},{"key":"BF00562501_CR12","first-page":"9","volume":"12","author":"J. Elis","year":"1966","unstructured":"\u2014\u2014 Ra\u0161kov\u00e1, H.: Controlled clinical trial with new cytostatic preparations produced in Czechoslovakia. Rev. Czech. Med.12, 9\u201319 (1966).","journal-title":"Rev. Czech. Med."},{"key":"BF00562501_CR13","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/cpt1970113404","volume":"11","author":"J. Elis","year":"1970","unstructured":"\u2014\u2014 Slav\u00edk, M., Ra\u0161kov\u00e1, H.: Side-effects of 6-azauridine triacetate in rheumatoid arthritis. Clin. Pharm. Ther.11, 404\u2013407 (1970).","journal-title":"Clin. Pharm. Ther."},{"key":"BF00562501_CR14","first-page":"153","volume":"I","author":"M.W. Elves","year":"1963","unstructured":"Elves, M.W., Buttoo, A.S., Israelstam, C.G., Wilkinson, J.F.: Chromosomal changes caused by 6-azauridine during treatment of acute myeloblastic leukemia. Brit. med. J.1963 I, 153\u2013159.","journal-title":"Brit. med. J."},{"key":"BF00562501_CR15","first-page":"115","volume":"14","author":"M. Falke","year":"1970","unstructured":"Falke, M., Rada, B.: 6-Azauridine as an inhibitor of the synthesis of herpes virus hominis. Acta Virol.14, 115\u2013123 (1970).","journal-title":"Acta Virol."},{"key":"BF00562501_CR16","first-page":"332","volume":"9","author":"G. Falkson","year":"1963","unstructured":"Falkson, G.: Halogenated pyrimidine and herpes simplex. Med. Proc.9, 332\u2013333 (1963).","journal-title":"Med. Proc."},{"key":"BF00562501_CR17","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1172\/JCI104415","volume":"40","author":"H.J. Fallon","year":"1961","unstructured":"Fallon, H.J., Frei, E., Block, L., Seegemiller, J.E.: The uricosuria and orotic aciduria induced by 6-azauridine. J. clin. Invest.40, 1906\u20131913 (1961).","journal-title":"J. clin. Invest."},{"key":"BF00562501_CR18","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/0006-2952(66)90265-6","volume":"15","author":"D.S. Fischer","year":"1966","unstructured":"Fischer, D.S., Cassidy, E.P., Welch, A.D.: Immunosupression by pyrimidine nucleoside analogs. Biochem. Pharmacol.15, 1013\u20131022 (1966).","journal-title":"Biochem. Pharmacol."},{"key":"BF00562501_CR19","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0025-7125(16)32915-7","volume":"52","author":"W.M. Fosdick","year":"1968","unstructured":"Fosdick, W.M.: Cytotoxic therapy in rheumatoid arthritis. Med. Clin. N. Amer.52, 747\u2013757 (1968).","journal-title":"Med. Clin. N. Amer."},{"key":"BF00562501_CR20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF00332389","volume":"28","author":"H. Frohberg","year":"1971","unstructured":"Frohberg, H.: The evaluation of mutagenicity tests within the scope of toxicological trial. Arch. Toxikol.28, 135\u2013148 (1971).","journal-title":"Arch. Toxikol."},{"key":"BF00562501_CR21","first-page":"351","volume":"15","author":"G.A. Galegov","year":"1970","unstructured":"Galegov, G.A., Kukhar, E.E., Bikbulatov, R.M.: Treatment of keratitis in rabbits due to herpes simplex virus with 6-azauridine (Russian). Voprosy Virologii15, 351\u2013354 (1970).","journal-title":"Voprosy Virologii"},{"key":"BF00562501_CR22","first-page":"142","volume-title":"Adjuvant induced disease in rats","author":"J. Grimov\u00e1","year":"1969","unstructured":"Grimov\u00e1, J.: Adjuvant induced disease in rats. Ph.D. Thesis. Research Institute of Pharmacy and Biochemistry, p. 142\u2013155, Prague, 1969."},{"key":"BF00562501_CR23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/tera.1420040304","volume":"4","author":"M. Gutov\u00e1","year":"1971","unstructured":"Gutov\u00e1, M., Elis, J., Ra\u0161kov\u00e1, H.: Teratogenic effect of 6-azauridine in rats. Teratology4, 287\u2013294 (1971).","journal-title":"Teratology"},{"key":"BF00562501_CR24","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1135\/cccc19582201","volume":"23","author":"V. Habermann","year":"1958","unstructured":"Habermann, V., \u0160orm, F.: Mechanism of the cancerostatic action of 6-azauracil and its riboside. Coll. Czech. Chem. Comm.23, 2201\u20132206, (1958).","journal-title":"Coll. Czech. Chem. Comm."},{"key":"BF00562501_CR25","unstructured":"Handbook for small-pox eradication. Programmes in the endemic areas. World Health Organization, June, 1967."},{"key":"BF00562501_CR26","first-page":"191","volume":"16","author":"R.E. Handschumacher","year":"1957","unstructured":"Handschumacher, R.E.: Metabolites of 6-azauracil formed by Streptococcus faecalis. Fed. Proc.16, 191 (1957).","journal-title":"Fed. Proc."},{"key":"BF00562501_CR27","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/0006-3002(57)90348-7","volume":"23","author":"R.E. Handschumacher","year":"1957","unstructured":"\u2014\u2014 Studies of bacterial resistance to 6-azauracil and its riboside. Biochim. biophys. Acta.23, 428\u2013430 (1957).","journal-title":"Biochim. biophys. Acta."},{"key":"BF00562501_CR28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0006-3002(58)90088-X","volume":"30","author":"R.E. Handschumacher","year":"1958","unstructured":"\u2014\u2014 Pasternak, C.A.: Inhibition of orotidylic acid decarboxylase, a primary site of carcinostatic by 6-azauracil. Biochim. biophys. Acta30, 451\u2013452 (1958).","journal-title":"Biochim. biophys. Acta"},{"key":"BF00562501_CR29","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1016\/S0021-9258(18)64562-4","volume":"235","author":"R.E. Handschumacher","year":"1960","unstructured":"\u2014\u2014 Orotidylic acid decarboxylase with azauridine 5\u2032-phosphate. J. biol. Chem.235, 2917\u20132919 (1960).","journal-title":"J. biol. Chem."},{"key":"BF00562501_CR30","first-page":"1","volume":"21","author":"R.E. Handschumacher","year":"1962","unstructured":"\u2014\u2014 Calabresi, P., Welch, A.D., Bono, V., Fallon, H.J., Frei: Summary of current information of 6-azauridine. Cancer Chemother. Rep.21, 1\u201318 (1962).","journal-title":"Cancer Chemother. Rep."},{"key":"BF00562501_CR31","first-page":"29","volume":"28","author":"S. Havelka","year":"1969","unstructured":"Havelka, S., P\u011bg\u0159imov\u00e1, E., Trnavsky, K., Slav\u00edk, M., Elis, J.: 6-Azauridin-Triacetat in der Therapie der chronischen Polyarthritis. Zeitschr. f. Rheumaforsch.28, 29\u201335 (1969).","journal-title":"Zeitschr. f. Rheumaforsch."},{"key":"BF00562501_CR32","first-page":"101","volume":"7","author":"C. Heidelberger","year":"1967","unstructured":"Heidelberger, C.: Cancer Chemotherapy with Purine and Pyrimidine Analogues. Ann. Res. Pharm.7, 101\u2013124 (1967).","journal-title":"Ann. Res. Pharm."},{"key":"BF00562501_CR33","first-page":"168","volume":"30","author":"J.J. Jaffe","year":"1957","unstructured":"Jaffe, J.J., Handschumacher, R.E., Welch, A.D.: Studies on the carcinostatic activity in mice of 6-azauracil riboside (azauridine) in comparison with that of 6-azauracil. Yale J. Biol. Med.30, 168\u2013175 (1957).","journal-title":"Yale J. Biol. Med."},{"key":"BF00562501_CR34","volume-title":"The possibilities of detection of adverse reactions of drugs from animal experiment","author":"I. Jank\u016f","year":"1967","unstructured":"Jank\u016f, I.: The possibilities of detection of adverse reactions of drugs from animal experiment. Thesis, Charles University, Prague, December, 1967."},{"key":"BF00562501_CR35","first-page":"17","volume":"6","author":"S. Jasi\u0148ska","year":"1962","unstructured":"Jasi\u0148ska, S., Link, F., Bla\u0161kovi\u010d, D., Rada, B.: Studies on the effect of antiviral substances on experimental virus infections. III. The effects of 6-azauracil riboside urethane on vaccinia virus infection in mice. Acta Virol.6, 17\u201323 (1962).","journal-title":"Acta Virol."},{"key":"BF00562501_CR36","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/0006-2952(65)90005-5","volume":"14","author":"Z. Ji\u0159i\u010dka","year":"1965","unstructured":"Ji\u0159i\u010dka, Z., Smetana, K., Jank\u016f, I., Elis, J., Novotn\u00fd, J.: Studies on 6-azauridine and 6-azacytidine. I. Toxicity studies of 6-azauridine and 6-azacytidine in mice. Biochem. Pharmacol.14, 1517\u20131523 (1965).","journal-title":"Biochem. Pharmacol."},{"key":"BF00562501_CR37","first-page":"161","volume":"19","author":"Z. M\u00edsa\u0159ov\u00e1","year":"1964","unstructured":"M\u00edsa\u0159ov\u00e1, Z., Elis, J.: The treatment of children leukemia with 6-azauracilriboside and its triacetate (In Czech). \u010cs. Pediatrie19, 161\u2013165 (1964).","journal-title":"\u010cs. Pediatrie"},{"key":"BF00562501_CR38","first-page":"266","volume":"12","author":"K. Nouza","year":"1966","unstructured":"Nouza, K.: Screening of immunosuppressive drugs in the allotransplantation reaction between mice differing at the 83-H locus. Folia Biologica12, 266\u2013277 (1966).","journal-title":"Folia Biologica"},{"key":"BF00562501_CR39","unstructured":"Scientific Information Service, United Pharmaceutical Works (SPOFA) Prague, 1960\u20131962."},{"key":"BF00562501_CR40","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1016\/S0021-9258(18)69710-8","volume":"234","author":"C.A. Pasternak","year":"1959","unstructured":"Pasternak, C.A., Handschumacher, R.E.: The biochemical activity of 6-azauridine: Interference with pyrimidine metabolism in transplantable mouse tumors. J. biol. Chem.234, 2992\u20132997 (1959).","journal-title":"J. biol. Chem."},{"key":"BF00562501_CR41","volume-title":"Pharmacokinetics of 6-azauridine triacetate","author":"J. Plevov\u00e1","year":"1969","unstructured":"Plevov\u00e1, J.: Pharmacokinetics of 6-azauridine triacetate (In Czech), Ph.D. Thesis, Charles University, Prague, 1969."},{"key":"BF00562501_CR42","first-page":"308","volume":"5","author":"B. Rada","year":"1961","unstructured":"Rada, B., Bla\u0161kovi\u010d, D.: Inhibitions of vaccinia virus multiplication in vitro by 6-azauracilriboside. Acta Virol.5, 308\u2013316, (1961).","journal-title":"Acta Virol."},{"key":"BF00562501_CR43","first-page":"1","volume":"10","author":"B. Rada","year":"1966","unstructured":"\u2014\u2014 \u2014\u2014 Some characteristics of the effects of 6-azauridine on vaccinia virus multiplication, in comparison with those of 5\u2032-iododeoxyuridine. Acta Virol.10, 1\u20139 (1966).","journal-title":"Acta Virol."},{"key":"BF00562501_CR44","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/BF02158350","volume":"16","author":"B. Rada","year":"1960","unstructured":"\u2014\u2014 \u2014\u2014 \u0160orm, F., \u0160koda, J.: The inhibitory effect of 6-azauracil riboside on the multiplication of vaccinia virus. Experientia16, 487\u2013488 (1960).","journal-title":"Experientia"},{"key":"BF00562501_CR45","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/0006-291X(64)90168-8","volume":"15","author":"B. Rada","year":"1964","unstructured":"\u2014\u2014 Gegu\u0161ov\u00e1, V.: Increase of uridine kinase activity after infection of cells with vaccinia and Rous sarcoma viruses. Biochem. biophys. Res. Commun.15, 324\u2013328 (1964).","journal-title":"Biochem. biophys. Res. Commun."},{"key":"BF00562501_CR46","unstructured":"Ra\u0161kov\u00e1, H., Elis, J.: Some new indications for 6-azauridine and 6-azauridine triacetate. Soc. Pharmacol. Hung. V. Conf. Hung. pro Therap. et Investigatione in Pharmacologia, p. 561\u2013565. Budapest 1968, ed. 1971."},{"key":"BF00562501_CR47","first-page":"258","volume":"6","author":"M. Rosenbergov\u00e1","year":"1962","unstructured":"Rosenbergov\u00e1, M., Rada, B.: Synthesis of cellular nucleic acids during inhibition of vaccinia virus multiplication by 6-azauracil riboside. Acta Virol.6, 258\u2013265 (1962).","journal-title":"Acta Virol."},{"key":"BF00562501_CR48","first-page":"247","volume":"2","author":"R. Schindler","year":"1957","unstructured":"Schindler, R., Welch, A.D.: Studies of inhibitory activity of 6-azauracil riboside and related compounds on Sarcoma 180 in tissue culture. Proc. Amer. Ass. Cancer Res.2, 247 (1957).","journal-title":"Proc. Amer. Ass. Cancer Res."},{"key":"BF00562501_CR49","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/BF00420718","volume":"2","author":"M. Slav\u00edk","year":"1970","unstructured":"Slav\u00edk, M., Elis, J., Ra\u0161kov\u00e1, H., Gutov\u00e1, M., Duchkov\u00e1, M., Kub\u00edkov\u00e1, M., Sey\u010dek, V.: Therapeutic effects of 6-azauridine triacetate in psoriasis. Pharm. Clin.2, 120\u2013125 (1970).","journal-title":"Pharm. Clin."},{"key":"BF00562501_CR50","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1135\/cccc19571330","volume":"22","author":"J. \u0160koda","year":"1957","unstructured":"\u0160koda, J., Hess, W.F., \u0160orm, F.: 1. Production of 6-azauracilriboside by Escherichia coli growing in the presence of 6-azauracil. Coll. Czech. Chem. Comm.22, 1330\u20131333 (1957).","journal-title":"Coll. Czech. Chem. Comm."},{"key":"BF00562501_CR51","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/BF02158141","volume":"13","author":"J. \u0160koda","year":"1957","unstructured":"\u2014\u2014 \u2014\u2014 \u2014\u2014 2. The biosynthesis of 6-azauracilriboside by Escherichia coli growing in the presence of 6-azauracil. Experientia13, 150\u2013151 (1957).","journal-title":"Experientia"},{"key":"BF00562501_CR52","first-page":"282","volume":"6","author":"F. \u0160mejkal","year":"1962","unstructured":"\u0160mejkal, F., \u0160orm, F.: The effect of 6-azauracil riboside against vaccinia virus in rabbits. Acta Virol.6, 282 (1962).","journal-title":"Acta Virol."},{"key":"BF00562501_CR53","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF02159094","volume":"14","author":"F. \u0160orm","year":"1958","unstructured":"\u0160orm, F., Keilov\u00e1, H.: The anti-tumour activity of 6-azauracil riboside. Experientia14, 215 (1958).","journal-title":"Experientia"},{"key":"BF00562501_CR54","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/1891022a0","volume":"189","author":"J. \u0160terzl","year":"1961","unstructured":"\u0160terzl, J.: Effect of some metabolic inhibitors on antibody formation. Nature189, 1022\u20131023 (1961).","journal-title":"Nature"},{"key":"BF00562501_CR55","doi-asserted-by":"crossref","first-page":"951","DOI":"10.7326\/0003-4819-73-6-951","volume":"73","author":"W.R. Vogler","year":"1970","unstructured":"Vogler, W.R., Olansky, S.: A double-blind study of azaribine in the treatment of psoriasis. Ann. int. Med.73, 951\u2013956 (1970).","journal-title":"Ann. int. Med."},{"key":"BF00562501_CR56","doi-asserted-by":"crossref","unstructured":"Z\u00e1ruba, F., K\u016fta, A., Elis, J.: The treatment of mycosis fungoides with 6-azauracilriboside. Lancet1963, No 7272, p. 275","DOI":"10.1016\/S0140-6736(63)91003-1"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00562501.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF00562501\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00562501","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00562501.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T14:12:59Z","timestamp":1684851179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF00562501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1972,3]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1972,3]]}},"alternative-id":["BF00562501"],"URL":"https:\/\/doi.org\/10.1007\/bf00562501","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[1972,3]]},"assertion":[{"value":"7 October 1971","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 1971","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}